Swittons Introduces IoT-Enabled Smart Devices for Pharmaceutical Labs
With the ability to be uniquely programmed, the devices provide user interfaces that can integrate with other systems and IoT devices, giving labs the ability to create their own Lab of the Future initiatives.
Swittons, a P360 company, introduced a new line of Internet of Things (IoT)-enabled smart devices for pharmaceutical labs. The devices work to automate laboratory workflows between people and existing digital lab equipment, systems, and solutions.
With the ability to be uniquely programmed, the devices provide user interfaces that can integrate with other systems and IoT devices, giving labs the ability to create their own Lab of the Future initiatives. Additionally, the new devices are compatible with laboratory information management systems, eDOC, and ticketing systems and feature a backend portal and reporting system.
“There are profound changes taking place in the area of life science research and development,” said Anupam Nandwana, Swittons’ CEO and founder, in an Aug. 11, 2020 company press release. “Driven by technological advances and the development of precision medicines, these modernization initiatives are designed to propel laboratory efficiencies into the future, allowing scientists to spend more time on science. This has changed the very concept of what the lab is, and Swittons is a key part of that evolution.”
Source: Swittons
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
